Sanofi announced it will present data from 45 abstracts, including four oral presentations, at the European Academy of Dermatology and Venereology (EADV) Congress in Paris from September 17 to 20, 2025. The presentations will cover both approved and investigational medicines for chronic inflammatory skin diseases.
The company, in partnership with Regeneron, will share new analyses on Dupixent (dupilumab) across conditions such as atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. Additionally, Sanofi will present first-time results from the HS-OBTAIN phase 2a study evaluating brivekimig—a dual-target nanobody inhibiting tumor necrosis factor (TNF) and OX40 ligand (OX40L)—in adults with moderate-to-severe hidradenitis suppurativa.
Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head of Immunology and Oncology Development at Sanofi said: “Our wide range of data being presented at EADV is a testament to our relentless focus onadvancing transformative therapies to treat patients living with a variety of chronic inflammatory skin diseases, many of whom are in urgent need of novel therapeutic options. Our Dupixent data builds on the growing body of evidence in atopic dermatitis, including clinical and real-world data evaluating longer-term outcomes in children as well as adult patients with skin of color. In addition, the first results for brivekimig in hidradenitis suppurativa support that targeting the OX40L pathway and TNF blockade together may be a promising strategy to reduce inflammation and improve HS.”
Among the highlights for Dupixent are studies from its clinical program focusing on various inflammatory skin diseases. These include an analysis examining Dupixent’s impact on growth in children with atopic dermatitis; evaluation of its effects on skin structure using 3D-imaging techniques in adults with skin of color; and long-term outcome studies up to four years for children with skin of color. Additional research assesses the burden and treatment outcomes for prurigo nodularis and chronic spontaneous urticaria.
Safety findings across these studies were generally consistent with previously known safety profiles for Dupixent in dermatological indications.
Sanofi will also present new data from its immunology pipeline. This includes studies evaluating brivekimig for hidradenitis suppurativa; amlitelimab for moderate-to-severe atopic dermatitis; rilzabrutinib for chronic spontaneous urticaria; and SAR445399—a novel IL1R3 monoclonal antibody—for reducing skin inflammation through IL1 and IL36 pathways. Brivekimig, amlitelimab, and rilzabrutinib remain investigational products without established efficacy or safety conclusions.
Dupixent is a fully human monoclonal antibody that inhibits interleukin 4 (IL4) and interleukin 13 (IL13) signaling but is not an immunosuppressant. It has received regulatory approvals in over 60 countries for multiple indications related to type-2 inflammation—including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, and bullous pemphigoid—in different age groups. More than one million patients worldwide are being treated with Dupixent.
The development program for dupilumab involves more than 60 clinical studies across over 10,000 patients affected by various chronic diseases linked to type-2 inflammation. Ongoing research includes investigations into other conditions such as chronic pruritus of unknown origin and lichen simplex chronicus.
Brivekimig targets both TNF and OX40L—key immune regulators—and is under investigation for several immune-mediated diseases beyond dermatology. Amlitelimab is designed to block OX40L without depleting T cells; it aims to restore immune balance while enabling quarterly dosing intervals. Rilzabrutinib is an oral BTK inhibitor developed using Sanofi’s TAILORED COVALENCY technology to selectively inhibit BTK while potentially minimizing off-target side effects.
Sanofi describes itself as an R&D-driven biopharma company focused on developing medicines and vaccines informed by its understanding of the immune system. The company states it applies artificial intelligence tools within its research efforts.
Sanofi trades publicly on EURONEXT: SAN and NASDAQ: SNY.
